Targeted protein degradation is becoming explored as an alternative approach in cancer, whereby the normal protein degradation process is co-opted for therapeutic needs. Just lately designed novel molecules known as proteolysis-focusing on chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. 1 ligand binds into the ‘protein https://www.directivepublications.org/journal-of-clinical-breast-cancer/